Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline
Journal of Clinical Oncology · 10.02.2023 · 41 (5) · 1132-1146
DOI: 10.1200/jco.22.02328 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.02.2023. Verfasst von Emrullah Yilmaz und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Cleveland, OH. Hauptthemen laut MEDLINE: Head and Neck Neoplasms. Die Arbeit wurde bisher 102-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
PURPOSE To provide evidence-based recommendations for practicing physicians and other health care providers on immunotherapy and biomarker testing for head and neck cancers. METHODS ASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, radiology, pathology, and patient advocacy experts to conduct a literature search, including systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2022. Outcomes of interest included survival, overall response, and locoregional control. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 28 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS When possible, evidence-based recommendations were developed to address biomarker testing, first-line treatment regimens based on programmed death ligand-1 scores, immunotherapy in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma, immunotherapy in nasopharyngeal carcinoma, and radiation therapy in combination with immunotherapy for treatment of local recurrence. Additional information is available at www.asco.org/head-neck-cancer-guidelines .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cleveland Clinic, Cleveland, OH.
- American Society of Clinical Oncology, Alexandria, VA.
- George Washington University, Washington, DC.
- The Center for Cancer and Blood Disorder, Southlake, TX.
- Kansas University Medical Center, Kansas City, KS.
- University of California San Francisco, San Francisco, CA.
ORCID-Profile: Emrullah Yilmaz, Nofisat Ismaila, Julie E Bauman, Marnie Kaufman, Kedar Kirtane, Sean Matthew McBride, Nabil F Saba, Siddharth Sheth, Rathan M Subramaniam, Trisha Michel Wise-Draper, Deborah Wong, Loren K Mell
Förderung
- NIGMS NIH HHS
Zitieren
APA
Yilmaz, E., Ismaila, N., Bauman, J. E., Dabney, R., Gan, G., Jordan, R., Kaufman, M., Kirtane, K., McBride, S. M., Old, M. O., Rooper, L., Saba, N. F., Sheth, S., Subramaniam, R. M., Wise-Draper, T. M., Wong, D., & Mell, L. K. (2023). Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. Journal of Clinical Oncology, 41(5), 1132-1146. https://doi.org/10.1200/jco.22.02328
Vancouver
Yilmaz E, Ismaila N, Bauman JE, Dabney R, Gan G, Jordan R, et al. Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. Journal of Clinical Oncology. 2023;41(5):1132-1146. doi:10.1200/jco.22.02328
BibTeX
@article{Yilmaz2023,
author = {Yilmaz, Emrullah and Ismaila, Nofisat and Bauman, Julie E and Dabney, Raetasha and Gan, Gregory and Jordan, Richard and Kaufman, Marnie and Kirtane, Kedar and McBride, Sean Matthew and Old, Matthew O and Rooper, Lisa and Saba, Nabil F and Sheth, Siddharth and Subramaniam, Rathan M and Wise-Draper, Trisha Michel and Wong, Deborah and Mell, Loren K},
title = {Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {5},
pages = {1132--1146},
doi = {10.1200/jco.22.02328}
}
EUVIMED